All posts by: Michael Zand

About Michael Zand

Ophthotech sponsors gene therapy research for retinal diseases – Healio

Continue reading

2018-02-27 NEWS

Ophthotech sponsors gene therapy research for retinal diseases
Healio
Ophthotech has begun a gene therapy research collaboration that will use novel gene therapy technology to discover and develop ocular disease treatments, according to a press release. The company has entered into sponsored research agreements with the
Ophthotech’s (OPHT) CEO Glenn Sblendorio on Q4 2017 Results – Earnings Call TranscriptSeeking Alpha

all 2 news articles »

Continue reading

2018-02-27 NEWS

Singularity Hub

Not Just Gene Editing—CRISPR Toolkit Expands With Trio of New Tricks
Singularity Hub
In a trio of studies released last week in Science, leading CRISPR labs around the world unveiled some ultra-creative additions to the technique, transforming the hotshot editor into a virus detective or a sharp-eyed historian jotting down a cell’s
A Review of CRISPR-Cas9: How is the Gene Editing Tool Changing the World?Labiotech.eu (blog)
What 3D printing can teach us about how to regulate CRISPR gene editingGenetic Literacy Project

all 4 news articles »

Continue reading

2018-02-27 NEWS

PR Web (press release)

The Next Big Advance in CAR T-cell Treatment Will Be Smarter Cell Therapy Production
Benzinga
Immunotherapy has emerged as the hottest trend in cancer care by creating “living drugs” that are able to recognize and kill a patient’s cancer cells without damaging healthy cells. Making those therapies, however, is cumbersome, slow and expensive
The Next Big Advance in CAR T-cell Treatment Will Be Smarter Cell …PR Web (press release)

all 1 news articles »

Continue reading

2018-02-27 NEWS

PR Web (press release)

The Next Big Advance in CAR T-cell Treatment Will Be Smarter Cell Therapy Production
PR Web (press release)
Immunotherapy has emerged as the hottest trend in cancer care by creating “living drugs” that are able to recognize and kill a patient’s cancer cells without damaging healthy cells. Making those therapies, however, is cumbersome, slow and expensive

and more »